Boosted by the success of the new epilepsy drug cenobamate

SK Biopharmaceuticals has ushered in the era of 200 billion won in annual operating profit, driven by the global success of its innovative epilepsy drug Xcopri.


According to SK Biopharmaceuticals' provisional earnings announcement on the 6th, last year's consolidated annual revenue came to 706.7 billion won, with operating profit of 203.9 billion won. Compared with the previous year, revenue jumped by 29.1% and operating profit surged by a remarkable 111.7%. This represents the strongest performance growth since the company's founding and marks the full-fledged improvement of profitability.

SK Biopharmaceuticals' Operating Profit Surpasses 200 Billion Won Last Year View original image

Fourth-quarter results were also solid. Revenue reached 194.3 billion won, up 19.2% from the same period a year earlier, while operating profit came in at 46.2 billion won, firmly cementing the earnings turnaround. Although operating profit fell 34% quarter-on-quarter due to selling, general, and administrative expenses such as marketing costs, on an annual basis the increase in revenue far outpaced the increase in costs, maximizing the so-called operating leverage effect.


Net profit also showed remarkable improvement. Last year's annual net profit was 253.2 billion won, up 11.6% from 226.9 billion won a year earlier. In particular, fourth-quarter net profit soared to 132.7 billion won, an 86% increase from the previous quarter's 71.3 billion won, a result attributed to efficient cost management as well as additional non-operating income.



This earnings growth was driven by the steep rise in prescriptions for cenobamate (brand name Xcopri), which the company sells directly in the United States. As the contribution of this high-margin new drug to total sales increased, the company is seen as having achieved both top-line growth and stronger fundamentals. Building on its newly secured robust cash-generating capacity, SK Biopharmaceuticals plans to expand investment in new modalities (therapeutic approaches) and accelerate its push to become a leading global biotech company.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing